Diassess said that the funds will accelerate development of a flu test for use in the clinic and sustain development of another flu test for use in the home.
The firm anticipates that the award will accelerate the development of its over-the-counter and professional-use influenza and multiplex respiratory pathogen tests.
The Fusion module is an in-lab upgrade to Hologic's Panther instrument, which enables labs to extend the testing capabilities of their existing Panther.
At the recent CVS, the two large health systems described introducing Cepheid platforms for flu testing across rural and satellite locations.
The firm is positioning the technology, called Morffi, for use in lateral flow immunoassays, particularly in infectious disease diagnostics, such as influenza tests.
Researchers at the University of Washington have developed a diagnostic platform that leverages the lateral flow immunoassay concept using quantum dots, a mobile phone, and an ultraviolet light-emitting diode.
Rapid immunoassay product revenues — including sales from the firm's QuickVue, Sofia, and Eye Health products — rose 40 percent year over year.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
Lifted by a strong flu season, Cobas Liat PCR placements reached 1,500 systems in the US. Globally, year-over-year sales for the point-of-care system grew 262 percent.
The platform, which was first developed to transmit flu data to the CDC, is expanding to multiple use cases and multiple users.